The proliferation of M-07e cells treated with increasing concentrations of hSCF was assessed. After 48 hour treatment with hSCF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant hSCF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hSCF and staining overnight with Coomassie Blue.
Western blot analysis of extracts from M-07e cells untreated or treated with hSCF for 5 minutes, using Phospho-c-Kit (Tyr719) Antibody #3391 (upper) and c-Kit Antibody #3392 (lower)
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hSCF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hSCF. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1 μg hSCF.
The bioactivity of recombinant hSCF was determined in a M-07e cell proliferation assay. The ED50 of each lot is between 2-6 ng/ml.
Recombinant hSCF contains no "tags" and the nonglycosylated protein has a calculated MW of 18,458. DTT-reduced and non-reduced protein migrate as 22-35 kDa polypeptides. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal EGICR of recombinant hSCF was verified by amino acid sequencing.
Recombinant human SCF (hSCF) Glu26-Ala189 (Accession #P21583) was expressed in human 293 cells at Cell Signaling Technology.
SCF is produced by endothelial cells, fibroblasts, keratinocytes, gut epithelial cells and tumor cells (1,2). SCF is critical for hematopoiesis and mast cell differentiation and has additional roles in survival and function of other cell types (1). Some tumor cell proliferation and invasiveness are promoted by SCF (3). Tumor-derived SCF appears to be involved in expansion of myeloid-derived suppressor cells that in-turn limits proliferation of tumor-infiltrating T-cells (4). SCF may have additional roles in the tumor microenvironment (2). SCF is either soluble or integral membrane and the form is dependant on variation in splicing or proteolytic release (1). SCF binds to the receptor tyrosine kinase c-kit and induces activation of the AKT, ERK, JNK and p38 pathways (5,6).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.